Association, American Psychiatric (2000). „Schizophrenia”. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Publishing, Inc. ISBN978-0-89042-024-9. Архивирано из оригинала 11. 06. 2008. г. Приступљено 4. 7. 2008.
O'Donovan MC, Williams NM, Owen MJ (октобар 2003). „Recent advances in the genetics of schizophrenia”. Hum. Mol. Genet. 12 Spec No 2: R125—33. PMID12952866. doi:10.1093/hmg/ddg302.
McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (јануар 2010). „Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies”. Int. J. Drug Policy. 21 (1): 10—9. PMID19783132. doi:10.1016/j.drugpo.2009.09.001.
O'Donovan MC, Craddock NJ, Owen MJ (јул 2009). „Genetics of psychosis; insights from views across the genome”. Hum. Genet. 126 (1): 3—12. PMID19521722. doi:10.1007/s00439-009-0703-0.
Crow, T. J. (јул 2008). „The 'big bang' theory of the origin of psychosis and the faculty of language”. Schizophrenia Research. 102 (1–3): 31—52. PMID18502103. doi:10.1016/j.schres.2008.03.010.
Os, Jim van (2004). „Does the urban environment cause psychosis?”. British Journal of Psychiatry. 184 (4): 287—288. PMID15056569. doi:10.1192/bjp.184.4.287.
Selten JP, Cantor-Graae E, Kahn RS (март 2007). „Migration and schizophrenia”. Current Opinion in Psychiatry. 20 (2): 111—115. PMID17278906. doi:10.1097/YCO.0b013e328017f68e.
Large M, Sharma S, Compton MT, Slade T, Nielssen O (јун 2011). „Cannabis use and earlier onset of psychosis: a systematic meta-analysis”. Arch. Gen. Psychiatry. 68 (6): 555—61. PMID21300939. doi:10.1001/archgenpsychiatry.2011.5.
Moore, THM; Zammit, S.; Lingford-Hughes, A.; et al. (2007). „Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review”. Lancet. 370 (9584): 319—328. PMID17662880. doi:10.1016/S0140-6736(07)61162-3.
Sewell, RA; Ranganathan, M; D'Souza,, D. C. (април 2009). „Cannabinoids and psychosis”. International review of psychiatry (Abingdon, England). 21 (2): 152—62. PMID19367509. doi:10.1080/09540260902782802.
Broome, M. R.; Woolley, J. B.; Tabraham, P.; et al. (2005). „What causes the onset of psychosis?”. Schizophr. Res. 79 (1): 23—34. PMID16198238. doi:10.1016/j.schres.2005.02.007.
Kurtz, M. M. (2005). „Neurocognitive impairment across the lifespan in schizophrenia: an update”. Schizophrenia Research. 74 (1): 15—26. PMID15694750. doi:10.1016/j.schres.2004.07.005.
Cohen AS, Docherty NM (2004). „Affective reactivity of speech and emotional experience in patients with schizophrenia”. Schizophrenia Research. 69 (1): 7—14. PMID15145465. doi:10.1016/S0920-9964(03)00069-0.
Horan WP, Blanchard JJ (2003). „Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping”. Schizophrenia Research. 60 (2–3): 271—83. PMID12591589. doi:10.1016/S0920-9964(02)00227-X.
Smith, B.; Fowler, D. G.; Freeman, D.; et al. (2006). „Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations”. Schizophr. Res. 86 (1–3): 181—8. PMID16857346. doi:10.1016/j.schres.2006.06.018.
Beck, AT (2004). „A Cognitive Model of Schizophrenia”. Journal of Cognitive Psychotherapy. 18 (3): 281—88. doi:10.1891/jcop.18.3.281.65649.
Bell V, Halligan PW, Ellis HD (2006). „Explaining delusions: a cognitive perspective”. Trends in Cognitive Science. 10 (5): 219—26. PMID16600666. doi:10.1016/j.tics.2006.03.004.
Jones HM, Pilowsky LS (2002). „Dopamine and antipsychotic drug action revisited”. British Journal of Psychiatry. 181: 271—275. PMID12356650. doi:10.1192/bjp.181.4.271.
Konradi C, Heckers S (2003). „Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment”. Pharmacology and Therapeutics. 97 (2): 153—79. PMID12559388. doi:10.1016/S0163-7258(02)00328-5.
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). „Effects of ketamine in normal and schizophrenic volunteers”. Neuropsychopharmacology. 25 (4): 455—67. PMID11557159. doi:10.1016/S0893-133X(01)00243-3.
Coyle JT, Tsai G, Goff D (2003). „Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia”. Annals of the New York Academy of Sciences. 1003: 318—27. PMID14684455. doi:10.1196/annals.1300.020.
Tuominen HJ, Tiihonen J, Wahlbeck K (2005). „Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis”. Schizophrenia Research. 72 (2–3): 225—34. PMID15560967. doi:10.1016/j.schres.2004.05.005.
Jakobsen, K. D.; Frederiksen, J. N.; Hansen, T.; et al. (2005). „Reliability of clinical ICD-10 schizophrenia diagnoses”. Nordic Journal of Psychiatry. 59 (3): 209—12. PMID16195122. doi:10.1080/08039480510027698.
de, M. B. Koning; Bloemen, O. J.; TA, van Amelsvoort; et al. (2009). „Early intervention in patients at ultra high risk of psychosis: benefits and risks”. Acta Psychiatr Scand. 119 (6): 426—42. PMID19392813. doi:10.1111/j.1600-0447.2009.01372.x.
Arendt, M; Rosenberg, R; Foldager, L; Perto, G; Munk-Jørgensen, P. (децембар 2005). „Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases”. The British journal of psychiatry : the journal of mental science. 187 (6): 510—5. PMID16319402. doi:10.1192/bjp.187.6.510.
McGrath, JJ; Lawlor, DA (1. 12. 2011). „The search for modifiable risk factors for schizophrenia”. The American Journal of Psychiatry. 168 (12): 1235—8. PMID22193665. doi:10.1176/appi.ajp.2011.11081300.
Becker T, Kilian R (2006). „Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?”. Acta Psychiatrica Scandinavica Supplement. 113 (429): 9—16. PMID16445476. doi:10.1111/j.1600-0447.2005.00711.x.
Wahlbeck K, Cheine MV, Essali A (2007). „Clozapine versus typical neuroleptic medication for schizophrenia”. The Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd. (2): CD000059. PMID10796289. doi:10.1002/14651858.CD000059.
Tandon, R.; Belmaker, R. H.; Gattaz, W. F.; et al. (2008). „World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia”. Schizophr. Res. 100 (1–3): 20—38. PMID18243663. doi:10.1016/j.schres.2007.11.033.
Lynch D, Laws KR, McKenna PJ (2010). „Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials”. Psychol Med. 40 (1): 9—24. PMID19476688. doi:10.1017/S003329170900590X.
Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C (2004). „Cognitive behaviour therapy for schizophrenia”. Cochrane Database Syst Rev (4): CD000524. PMID15495000. doi:10.1002/14651858.CD000524.pub2.
Saha S, Chant D, McGrath J (2007). „A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?”. Arch. Gen. Psychiatry. 64 (10): 1123—31. PMID17909124. doi:10.1001/archpsyc.64.10.1123.
Ustun, T. B.; Rehm, J.; Chatterji, S.; Saxena, S.; Trotter, R.; Room, R.; Bickenbach, J. (1999). „Multiple-informant ranking of the disabling effects of different health conditions in 14 countries”. The Lancet. WHO/NIH Joint Project CAR Study Group. 354 (9173): 111—15. PMID10408486. doi:10.1016/S0140-6736(98)07507-2.
Palmer BA, Pankratz VS, Bostwick JM (2005). „The lifetime risk of suicide in schizophrenia: a reexamination”. Archives of General Psychiatry. 62 (3): 247—53. PMID15753237. doi:10.1001/archpsyc.62.3.247.
Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P (2010). „Suicide in schizophrenia”. Expert Rev Neurother. 10 (7): 1153—64. PMID20586695. doi:10.1586/ern.10.82.
De Leon J, Diaz FJ (2005). „A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors”. Schizophrenia research. 76 (2-3): 135—57. PMID15949648. doi:10.1016/j.schres.2005.02.010.
Castle D, Wessely S, Der G, Murray RM (1991). „The incidence of operationally defined schizophrenia in Camberwell, 1965–84”. The British Journal of Psychiatry. 159: 790—4. PMID1790446. doi:10.1192/bjp.159.6.790.
Jablensky, Sartorius & Ernberg 1992, стр. 1–97 Jablensky, A.; Sartorius, N.; Ernberg, G.; et al. (1992). „Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study”. Psychological Medicine Monograph Supplement. 20: 1—97. PMID1565705. doi:10.1017/S0264180100000904.
Kirkbride, J. B.; Fearon, P.; Morgan, C.; et al. (2006). „Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study”. Archives of General Psychiatry. 63 (3): 250—8. PMID16520429. doi:10.1001/archpsyc.63.3.250.
Kirkbride, J. B.; Fearon, P.; Morgan, C.; et al. (2007). „Neighbourhood variation in the incidence of psychotic disorders in Southeast London”. Social Psychiatry and Psychiatric Epidemiology. 42 (6): 438—45. PMID17473901. doi:10.1007/s00127-007-0193-0.
Kuhn, R. (2004). tr. Cahn CH. „Eugen Bleuler's concepts of psychopathology”. History of Psychiatry. 15 (3): 361—6. PMID15386868. doi:10.1177/0957154X04044603.
Large, M; Smith, G; Nielssen, O. (јул 2009). „The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis”. Schizophrenia research. 112 (1–3): 123—9. PMID19457644. doi:10.1016/j.schres.2009.04.004.
Batinic, B. (јун 2019). „Cognitive Models of Positive and Negative Symptoms of Schizophrenia and Implications for Treatment”. Psychiatr Danub. 31 (Suppl 2): 181—184. PMID31158119.CS1 одржавање: Формат датума (веза).
O'Donovan MC, Williams NM, Owen MJ (октобар 2003). „Recent advances in the genetics of schizophrenia”. Hum. Mol. Genet. 12 Spec No 2: R125—33. PMID12952866. doi:10.1093/hmg/ddg302.
McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (јануар 2010). „Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies”. Int. J. Drug Policy. 21 (1): 10—9. PMID19783132. doi:10.1016/j.drugpo.2009.09.001.
O'Donovan MC, Craddock NJ, Owen MJ (јул 2009). „Genetics of psychosis; insights from views across the genome”. Hum. Genet. 126 (1): 3—12. PMID19521722. doi:10.1007/s00439-009-0703-0.
Crow, T. J. (јул 2008). „The 'big bang' theory of the origin of psychosis and the faculty of language”. Schizophrenia Research. 102 (1–3): 31—52. PMID18502103. doi:10.1016/j.schres.2008.03.010.
Os, Jim van (2004). „Does the urban environment cause psychosis?”. British Journal of Psychiatry. 184 (4): 287—288. PMID15056569. doi:10.1192/bjp.184.4.287.
Selten JP, Cantor-Graae E, Kahn RS (март 2007). „Migration and schizophrenia”. Current Opinion in Psychiatry. 20 (2): 111—115. PMID17278906. doi:10.1097/YCO.0b013e328017f68e.
Large M, Sharma S, Compton MT, Slade T, Nielssen O (јун 2011). „Cannabis use and earlier onset of psychosis: a systematic meta-analysis”. Arch. Gen. Psychiatry. 68 (6): 555—61. PMID21300939. doi:10.1001/archgenpsychiatry.2011.5.
Moore, THM; Zammit, S.; Lingford-Hughes, A.; et al. (2007). „Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review”. Lancet. 370 (9584): 319—328. PMID17662880. doi:10.1016/S0140-6736(07)61162-3.
Sewell, RA; Ranganathan, M; D'Souza,, D. C. (април 2009). „Cannabinoids and psychosis”. International review of psychiatry (Abingdon, England). 21 (2): 152—62. PMID19367509. doi:10.1080/09540260902782802.
Broome, M. R.; Woolley, J. B.; Tabraham, P.; et al. (2005). „What causes the onset of psychosis?”. Schizophr. Res. 79 (1): 23—34. PMID16198238. doi:10.1016/j.schres.2005.02.007.
Kurtz, M. M. (2005). „Neurocognitive impairment across the lifespan in schizophrenia: an update”. Schizophrenia Research. 74 (1): 15—26. PMID15694750. doi:10.1016/j.schres.2004.07.005.
Cohen AS, Docherty NM (2004). „Affective reactivity of speech and emotional experience in patients with schizophrenia”. Schizophrenia Research. 69 (1): 7—14. PMID15145465. doi:10.1016/S0920-9964(03)00069-0.
Horan WP, Blanchard JJ (2003). „Emotional responses to psychosocial stress in schizophrenia: the role of individual differences in affective traits and coping”. Schizophrenia Research. 60 (2–3): 271—83. PMID12591589. doi:10.1016/S0920-9964(02)00227-X.
Smith, B.; Fowler, D. G.; Freeman, D.; et al. (2006). „Emotion and psychosis: links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations”. Schizophr. Res. 86 (1–3): 181—8. PMID16857346. doi:10.1016/j.schres.2006.06.018.
Bell V, Halligan PW, Ellis HD (2006). „Explaining delusions: a cognitive perspective”. Trends in Cognitive Science. 10 (5): 219—26. PMID16600666. doi:10.1016/j.tics.2006.03.004.
Green, M. F. (2006). „Cognitive impairment and functional outcome in schizophrenia and bipolar disorder”. Journal of Clinical Psychiatry. 67 (Suppl 9): 3—8. PMID16965182.
Jones HM, Pilowsky LS (2002). „Dopamine and antipsychotic drug action revisited”. British Journal of Psychiatry. 181: 271—275. PMID12356650. doi:10.1192/bjp.181.4.271.
Konradi C, Heckers S (2003). „Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment”. Pharmacology and Therapeutics. 97 (2): 153—79. PMID12559388. doi:10.1016/S0163-7258(02)00328-5.
Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). „Effects of ketamine in normal and schizophrenic volunteers”. Neuropsychopharmacology. 25 (4): 455—67. PMID11557159. doi:10.1016/S0893-133X(01)00243-3.
Coyle JT, Tsai G, Goff D (2003). „Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia”. Annals of the New York Academy of Sciences. 1003: 318—27. PMID14684455. doi:10.1196/annals.1300.020.
Tuominen HJ, Tiihonen J, Wahlbeck K (2005). „Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis”. Schizophrenia Research. 72 (2–3): 225—34. PMID15560967. doi:10.1016/j.schres.2004.05.005.
Jakobsen, K. D.; Frederiksen, J. N.; Hansen, T.; et al. (2005). „Reliability of clinical ICD-10 schizophrenia diagnoses”. Nordic Journal of Psychiatry. 59 (3): 209—12. PMID16195122. doi:10.1080/08039480510027698.
McGlashan, T. H. (1987). „Testing DSM-III symptom criteria for schizotypal and borderline personality disorders”. Archives of General Psychiatry. 44 (2): 143—8. PMID3813809.
de, M. B. Koning; Bloemen, O. J.; TA, van Amelsvoort; et al. (2009). „Early intervention in patients at ultra high risk of psychosis: benefits and risks”. Acta Psychiatr Scand. 119 (6): 426—42. PMID19392813. doi:10.1111/j.1600-0447.2009.01372.x.
Arendt, M; Rosenberg, R; Foldager, L; Perto, G; Munk-Jørgensen, P. (децембар 2005). „Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases”. The British journal of psychiatry : the journal of mental science. 187 (6): 510—5. PMID16319402. doi:10.1192/bjp.187.6.510.
McGrath, JJ; Lawlor, DA (1. 12. 2011). „The search for modifiable risk factors for schizophrenia”. The American Journal of Psychiatry. 168 (12): 1235—8. PMID22193665. doi:10.1176/appi.ajp.2011.11081300.
Becker T, Kilian R (2006). „Psychiatric services for people with severe mental illness across western Europe: what can be generalized from current knowledge about differences in provision, costs and outcomes of mental health care?”. Acta Psychiatrica Scandinavica Supplement. 113 (429): 9—16. PMID16445476. doi:10.1111/j.1600-0447.2005.00711.x.
Kane JM, Correll CU (2010). „Pharmacologic treatment of schizophrenia”. Dialogues Clin Neurosci. 12 (3): 345—57. PMID20954430.
Schultz SH, North SW, Shields CG (2007). „Schizophrenia: a review”. American Family Physician. 75 (12): 1821—9. PMID17619525.
Wahlbeck K, Cheine MV, Essali A (2007). „Clozapine versus typical neuroleptic medication for schizophrenia”. The Cochrane Database of Systematic Reviews. John Wiley and Sons, Ltd. (2): CD000059. PMID10796289. doi:10.1002/14651858.CD000059.
Tandon, R.; Belmaker, R. H.; Gattaz, W. F.; et al. (2008). „World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia”. Schizophr. Res. 100 (1–3): 20—38. PMID18243663. doi:10.1016/j.schres.2007.11.033.
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). „Neuroleptic malignant syndrome and atypical antipsychotic drugs”. Journal of Clinical Psychiatry. 65 (4): 464—70. PMID15119907. doi:10.4088/JCP.v65n0403.
McEvoy, J. P. (2006). „Risks versus benefits of different types of long-acting injectable antipsychotics”. Journal of Clinical Psychiatry. 67 Suppl 5: 15—8. PMID16822092.
Lynch D, Laws KR, McKenna PJ (2010). „Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials”. Psychol Med. 40 (1): 9—24. PMID19476688. doi:10.1017/S003329170900590X.
Jones C, Cormac I, Silveira da Mota Neto JI, Campbell C (2004). „Cognitive behaviour therapy for schizophrenia”. Cochrane Database Syst Rev (4): CD000524. PMID15495000. doi:10.1002/14651858.CD000524.pub2.
Saha S, Chant D, McGrath J (2007). „A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?”. Arch. Gen. Psychiatry. 64 (10): 1123—31. PMID17909124. doi:10.1001/archpsyc.64.10.1123.
Ustun, T. B.; Rehm, J.; Chatterji, S.; Saxena, S.; Trotter, R.; Room, R.; Bickenbach, J. (1999). „Multiple-informant ranking of the disabling effects of different health conditions in 14 countries”. The Lancet. WHO/NIH Joint Project CAR Study Group. 354 (9173): 111—15. PMID10408486. doi:10.1016/S0140-6736(98)07507-2.
Isaac M, Chand P, Murthy P (2007). „Schizophrenia outcome measures in the wider international community”. Br J Psychiatry Suppl. 50: s71—7. PMID18019048.
Burns J. (2009). „Dispelling a myth: developing world poverty, inequality, violence and social fragmentation are not good for outcome in schizophrenia”. Afr J Psychiatry (Johannesbg). 12 (3): 200—5. PMID19894340.
Palmer BA, Pankratz VS, Bostwick JM (2005). „The lifetime risk of suicide in schizophrenia: a reexamination”. Archives of General Psychiatry. 62 (3): 247—53. PMID15753237. doi:10.1001/archpsyc.62.3.247.
Carlborg A, Winnerbäck K, Jönsson EG, Jokinen J, Nordström P (2010). „Suicide in schizophrenia”. Expert Rev Neurother. 10 (7): 1153—64. PMID20586695. doi:10.1586/ern.10.82.
De Leon J, Diaz FJ (2005). „A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors”. Schizophrenia research. 76 (2-3): 135—57. PMID15949648. doi:10.1016/j.schres.2005.02.010.
Castle D, Wessely S, Der G, Murray RM (1991). „The incidence of operationally defined schizophrenia in Camberwell, 1965–84”. The British Journal of Psychiatry. 159: 790—4. PMID1790446. doi:10.1192/bjp.159.6.790.
Jablensky, Sartorius & Ernberg 1992, стр. 1–97 Jablensky, A.; Sartorius, N.; Ernberg, G.; et al. (1992). „Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study”. Psychological Medicine Monograph Supplement. 20: 1—97. PMID1565705. doi:10.1017/S0264180100000904.
Kirkbride, J. B.; Fearon, P.; Morgan, C.; et al. (2006). „Heterogeneity in incidence rates of schizophrenia and other psychotic syndromes: findings from the 3-center AeSOP study”. Archives of General Psychiatry. 63 (3): 250—8. PMID16520429. doi:10.1001/archpsyc.63.3.250.
Kirkbride, J. B.; Fearon, P.; Morgan, C.; et al. (2007). „Neighbourhood variation in the incidence of psychotic disorders in Southeast London”. Social Psychiatry and Psychiatric Epidemiology. 42 (6): 438—45. PMID17473901. doi:10.1007/s00127-007-0193-0.
Kuhn, R. (2004). tr. Cahn CH. „Eugen Bleuler's concepts of psychopathology”. History of Psychiatry. 15 (3): 361—6. PMID15386868. doi:10.1177/0957154X04044603.
Large, M; Smith, G; Nielssen, O. (јул 2009). „The relationship between the rate of homicide by those with schizophrenia and the overall homicide rate: a systematic review and meta-analysis”. Schizophrenia research. 112 (1–3): 123—9. PMID19457644. doi:10.1016/j.schres.2009.04.004.
Association, American Psychiatric (2000). „Schizophrenia”. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Publishing, Inc. ISBN978-0-89042-024-9. Архивирано из оригинала 11. 06. 2008. г. Приступљено 4. 7. 2008.